YMAB: Y-mAbs Therapeutics Inc Company Total Revenue

Corporate emblem and logo of ymabs.com (YMAB)

Y-mAbs Therapeutics management is currently revising its commercial plan and optimizing expenses. The company's gross sales on this chart demonstrate revenue dynamics, where the 0.09 indicator determines the metric's magnitude. Revenues are based on the commercialization of Danyelza therapy and the development of radioimmunotherapy methods. Sales are focused on pediatric oncology, with payments provided by government funds and insurance organizations.

YMAB Y-mAbs Therapeutics Company Revenue (07/04/2022 - 09/27/2025)

Comprehensive metric breakdowns and analytics for YmAbs (YMAB)

- market price and analyst price targets:
Comprehensive company analysis:Y-mAbs Therapeutics
Core merchandise of Y-mAbs Therapeutics Inc

Y-mAbs Therapeutics sales reflect the daily cash inflow from product realization, allowing for an assessment of current operational efficiency. This metric helps investors compare the actual revenue pace with the business's long-term quarterly goals. By analyzing the company's sales figures on the GURU.Markets platform, one can promptly detect signs of stagnation or growth. For Y-mAbs Therapeutics, such price action confirms the commercial success of its targeted antibodies. High physician confidence in pediatric oncology drugs ensures the stability of this cash flow.

Competing companies

Company Revenue ONC|Revenue and Sales Volume HALO|RVMD (Revolution Medicines, Inc.) - Company Sales Revenue|Company Revenue Ascentage Pharma Corp AAPG|Company Total Sales Volume CG Oncology, Inc.|URGN - Company Revenue|Bicara Therapeutics Inc. (BCAX) - Company Sales|Personalis Inc (PSNL) - Company Revenue|ERAS - Company Gross Revenue|DCTH (Delcath Systems Inc) - Revenue and Sales Volume|AURA: Company Sales Revenue|Company Revenue Candel Therapeutics, Inc. (CADL)|Revenue and Sales Volume Accuray (ARAY)|Company Revenue SELLAS Life Sciences Group Inc. SLS|Actuate Therapeutics, Inc (ACTU) - Company Total Revenue|CTOR - Company Revenue|HURA: Company Revenue|TARA (Protara) - Company Sales|Fate Therapeutics, Inc. - Company Sales Revenue|WHWK (aadibio.com) - Revenue and Sales Volume|TCRX: Company Sales Revenue|Company Revenue Champions Oncology (CSBR)|XBiotech - Company Sales Volume|Company Revenue CEL-SCI CVM|Company Gross Revenue OS Therapies (OSTX)|Radiopharm Theranostics Limited - Revenue and Sales Volume|Company Total Revenue Artiva Biotherapeutics|ANL (adlainortye.com) - Company Sales|Company Sales Veru Pharma|TPST (Tempest Therapeutics Inc) - Revenue and Sales Volume|Xilio Therapeutics, Inc. (XLO) - Company Gross Revenue|Company Revenue Enochian BioSciences (RENB)|MURA: Company Annual Revenue|Revenue and Sales Volume KAPA (kairospharma.com)|Company Gross Revenue OnKure (OKUR)|CytoMed Therapeutics Ltd - Revenue and Sales Volume|curis.com (CRIS) - Company Sales|Apollomics Corp (APLM) - Company Revenue|Tharimmune - Company Sales Revenue|ADVB (Advanced Biomed Corp) - Revenue and Sales Volume|Company Sales Genprex, Inc (GNPX)|Revenue and Sales Volume CLDI|SBFM: Company Annual Revenue|Revenue and Sales Volume XBIO (xeneticbio.com)|Revenue and Sales Volume Salarius Pharmaceuticals Inc SLRX|purple-biotech.com - Revenue and Sales Volume|Company Total Revenue American Oncology Network, Inc.|BGNE: Revenue and Sales Volume|Company Sales checkpointtx.com|Company Revenue Elevation Oncology, Inc.|iCAD, Inc. (ICAD) - Company Gross Revenue|Company Revenue Ikena (IKNA)|NTBL - Company Total Revenue|Company Revenue viracta.com VIRX|morphosys.com (MOR) - Company Total Revenue|NAYA Biosciences Inc - Revenue and Sales Volume|AAPGV: Company Revenue